DIAGNOSTIC REPORT
MC-7066
PATIENT NAME : ASHOK SHAH REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000111181 ACCESSION NO : 0290YG003770 AGE/SEX : 67 Years Male
KRISHNA DIAGNOSTICS PATIENT ID : ASHOM293459030 DRAWN : 16/07/2025 [Link]
45-A, BAKHTAWAR RAM NAGAR,INDORE
CLIENT PATIENT ID: RECEIVED : 16/07/2025 [Link]
INDORE 452018
ABHA NO : REPORTED : 16/07/2025 [Link]
7000588176
Test Report Status Final Results Biological Reference Interval Units
HAEMATOLOGY - CBC
ANTENATAL PANEL
BLOOD COUNTS, EDTA WHOLE BLOOD
HEMOGLOBIN (HB) 15.7 13.0 - 17.0 g/dL
METHOD : SPECTROPHOTOMETRY
RED BLOOD CELL (RBC) COUNT 5.27 4.5 - 5.5 mil/µL
METHOD : ELECTRICAL IMPEDANCE
WHITE BLOOD CELL (WBC) COUNT 7.35 4 - 10 thou/µL
METHOD : ELECTRICAL IMPEDANCE
PLATELET COUNT 378 150 - 410 thou/µL
METHOD : ELECTRICAL IMPEDANCE
RBC AND PLATELET INDICES
HEMATOCRIT (PCV) 47.2 40.0 - 50.0 %
METHOD : CALCULATED
MEAN CORPUSCULAR VOLUME (MCV) 89.4 83.0 - 101.0 fL
METHOD : CALCULATED
MEAN CORPUSCULAR HEMOGLOBIN (MCH) 29.8 27.0 - 32.0 pg
METHOD : CALCULATED
MEAN CORPUSCULAR HEMOGLOBIN 33.3 31.5 - 34.5 g/dL
CONCENTRATION(MCHC)
METHOD : CALCULATED
RED CELL DISTRIBUTION WIDTH (RDW) 12.2 11.6 - 14.0 %
METHOD : CALCULATED
MEAN PLATELET VOLUME (MPV) 8.5 6.8 - 10.9 fL
METHOD : CALCULATED
WBC DIFFERENTIAL COUNT
NEUTROPHILS 52 40 - 80 %
METHOD : IMPEDANCE / MICROSCOPY
LYMPHOCYTES 40 20 - 40 %
METHOD : MICROSCOPIC EXAMINATION
MONOCYTES 04 2.0 - 10.0 %
METHOD : MICROSCOPIC EXAMINATION
Page 1 Of 6
[Link] Pasari, MD
Consultant Pathologist
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001 ULR No.775000013358972-0290
Madhya Pradesh, India
Tel : 0731 2490008
DIAGNOSTIC REPORT
MC-7066
PATIENT NAME : ASHOK SHAH REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000111181 ACCESSION NO : 0290YG003770 AGE/SEX : 67 Years Male
KRISHNA DIAGNOSTICS PATIENT ID : ASHOM293459030 DRAWN : 16/07/2025 [Link]
45-A, BAKHTAWAR RAM NAGAR,INDORE
CLIENT PATIENT ID: RECEIVED : 16/07/2025 [Link]
INDORE 452018
ABHA NO : REPORTED : 16/07/2025 [Link]
7000588176
Test Report Status Final Results Biological Reference Interval Units
EOSINOPHILS 04 1-6 %
METHOD : MICROSCOPIC EXAMINATION
BASOPHILS 00 0-2 %
METHOD : MICROSCOPIC EXAMINATION
ABSOLUTE NEUTROPHIL COUNT 3.82 2-7 thou/µL
METHOD : CALCULATED PARAMETER
ABSOLUTE LYMPHOCYTE COUNT 2.94 1.0 - 3.0 thou/µL
METHOD : CALCULATED PARAMETER
ABSOLUTE MONOCYTE COUNT 0.29 0.20 - 1.00 thou/µL
METHOD : CALCULATED PARAMETER
ABSOLUTE EOSINOPHIL COUNT 0.29 0.02 - 0.50 thou/µL
Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)
from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2
remains the gold standard for diagnosing a case of beta thalassaemia trait.
WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive
patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <
3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al.
International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.
Page 2 Of 6
[Link] Pasari, MD
Consultant Pathologist
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001 ULR No.775000013358972-0290
Madhya Pradesh, India
Tel : 0731 2490008
DIAGNOSTIC REPORT
MC-7066
PATIENT NAME : ASHOK SHAH REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000111181 ACCESSION NO : 0290YG003770 AGE/SEX : 67 Years Male
KRISHNA DIAGNOSTICS PATIENT ID : ASHOM293459030 DRAWN : 16/07/2025 [Link]
45-A, BAKHTAWAR RAM NAGAR,INDORE
CLIENT PATIENT ID: RECEIVED : 16/07/2025 [Link]
INDORE 452018
ABHA NO : REPORTED : 16/07/2025 [Link]
7000588176
Test Report Status Final Results Biological Reference Interval Units
BIOCHEMISTRY
ANTENATAL PANEL
GLUCOSE
GLUCOSE RANDOM, FLUORIDE PLASMA
FASTING,FLUORIDE PLASMA
Non-Diabetic: < 200
132 High mg/dL
mg/dL
FBS (FASTING BLOOD
RBS ( RANDOM SUGAR)
BLOOD SUGAR) (Normal <100,Impaired
Diabetic: > or = 200 fasting
"In individuals
glucose:100 with
to 125,Diabetes
symptoms of
mellitus:>=126(on more than
hyperglycemia or
1 occasion)(ADA guidelines
hyperglycemic crisis."
2024)
METHOD : HEXOKINASE
Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION
Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the
urine.
Increased in:Diabetes mellitus, Cushing’ s syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.
Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,
malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases([Link]),Drugs-insulin,ethanol,propranolol
sulfonylureas,tolbutamide,and other oral hypoglycemic agents.
NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within
[Link], glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.
High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment,Renal Glyosuria,Glycaemic
index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc.
Page 4 Of 6
[Link] Pasari, MD
Consultant Pathologist
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001 ULR No.775000013358972-0290
Madhya Pradesh, India
Tel : 0731 2490008
DIAGNOSTIC REPORT
MC-7066
PATIENT NAME : ASHOK SHAH REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000111181 ACCESSION NO : 0290YG003770 AGE/SEX : 67 Years Male
KRISHNA DIAGNOSTICS PATIENT ID : ASHOM293459030 DRAWN : 16/07/2025 [Link]
45-A, BAKHTAWAR RAM NAGAR,INDORE
CLIENT PATIENT ID: RECEIVED : 16/07/2025 [Link]
INDORE 452018
ABHA NO : REPORTED : 16/07/2025 [Link]
7000588176
Test Report Status Final Results Biological Reference Interval Units
SEROLOGY
ANTENATAL PANEL
HEPATITIS B SURFACE ANTIGEN(RAPID), SERUM
HEPATITIS B SURFACE ANTIGEN NON REACTIVE NON REACTIVE
METHOD : IMMUNOCHROMATOGRAPHY
HIV ANTIBODIES(RAPID), SERUM
HIV-1 ANTIBODIES NON REACTIVE NON REACTIVE
HIV-2 ANTIBODIES NON REACTIVE NON REACTIVE
Interpretation(s)
HEPATITIS B SURFACE ANTIGEN(RAPID), SERUM-Hepatitis B is caused by infection with HBV, a enveloped DNA agent that is classified as [Link] test detects the
presence of viral surface antigen (HbsAg) in serum sample and is indicative of an active HBV infection, either acute or chronic.
Test Utility:
HbsAg is the first serologic marker appearing in the serum 6-16 weeks following hepatitis B viral infection. In typical HBV infection, HBsAg will be detected 2-4 weeks before
the liver enzyme levels (ALT) become abnormal and 3-5 weeks before patient develops [Link] acute cases HbsAg usually disappears 1-2 months after the onset of
[Link] of HbsAg for more than 6 months indicates development of either a chronic carrier state or chronic liver [Link] presence of HbsAg is frequently
associated with infectivity. HbsAg when accompanied by Hepatitis Be antigen and/or hepatitis B viral DNA almost always indicates infectivity.
Limitations:
- For diagnostic purposes, results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute or chronic infection. If the antibody
results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
- HBsAg detection will only indicate the presence of surface antigens in the serum and should not be used as the sole criteria for diagnosis, staging or monitoring of HBV
infection This test may be negative during ""window period"" i.e. after disappearance of anti-HBs.
- The current assay being a highly sensitive test , may yield a small percentage of false positive reports. Hence all HbsAg positive specimens should be confirmed with an
assay based upon Neutralisation of Human anti Hepatitis B Surface antibody.
HIV ANTIBODIES(RAPID), SERUM-Acquired immunodeficiency syndrome (AIDS) is caused by 2 types of human immunodeficiency viruses, collectively designated HIV. HIV is
transmitted by sexual contact, exposure to blood or blood products, and prenatal infection of a fetus or perinatal infection of a newborn.
Phylogenetic analysis classifies HIV-1 into groups M (major), N (non-M, non-O), and O (outlier).HIV-2 is similar to HIV-1 in its structural morphology, genomic organization,
cell tropism, in vitro cytopathogenicity, transmission routes, and ability to cause AIDS. However, HIV-2 is less pathogenic than [Link]-2 infections have a longer latency
period with slower progression to disease, lower viral titers, and lower rates of vertical and horizontal transmission. HIV-2 is endemic to West Africa but HIV-2 infections, at
a low frequency compared to HIV-1, have been identified in the USA, Europe, Asia, and other regions of [Link] predominantly has HIV-1M subtype C.
Test Utility
The test is used as an aid in the diagnosis of HIV-1/HIV-2 infection .
If HIV reactive result is obtained, confirmation of HIV antibody status is done using 2 more antibody tests ( as per NACO guidelines-Strategy III algorithm) . If indicated HIV
serostatus may be confirmed by repeating antibody test on fresh specimen or HIV-1 Western Blot (Immunoblot) Assay (Agilus test code #3012).
Limitations:
- Antibody tests may give false negative during the window period, an interval of 3 weeks to 6 months between the time of HIV infection and the production of measurable
antibodies to HIV seroconversion. Most people develop detectable antibodies approximately 30 days after infection, although some seroconvert later. The vast majority of
people (97%) have detectable antibodies by three months after HIV infection a 6-month window is extremely rare with modern antibody testing.
- Early antiretroviral therapy during the window period may alter antibody responses. This does not apply to individuals undergoing treatment with post-exposure
prophylaxis (PEP).
- Antibody tests may yield false negative results in patients with X-linked agammaglobulinemia.
Page 5 Of 6
[Link] Pasari, MD
Consultant Pathologist
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001 ULR No.775000013358972-0290
Madhya Pradesh, India
Tel : 0731 2490008
DIAGNOSTIC REPORT
MC-7066
PATIENT NAME : ASHOK SHAH REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000111181 ACCESSION NO : 0290YG003770 AGE/SEX : 67 Years Male
KRISHNA DIAGNOSTICS PATIENT ID : ASHOM293459030 DRAWN : 16/07/2025 [Link]
45-A, BAKHTAWAR RAM NAGAR,INDORE
CLIENT PATIENT ID: RECEIVED : 16/07/2025 [Link]
INDORE 452018
ABHA NO : REPORTED : 16/07/2025 [Link]
7000588176
Test Report Status Final Results Biological Reference Interval Units
- A positive HIV result in an infant <18 months of age may not reflect the infants HIV infection [Link] antibodies persist in the sera of infants upto 18 months of age,
due to transplacentally acquired maternal antibodies. HIV PCR testing is recommended in this age group for diagnosis.
**End Of Report**
Please visit [Link] for related Test Information for this accession
CONDITIONS OF LABORATORY TESTING & REPORTING
1. It is presumed that the test sample belongs to the patient 5. AGILUS Diagnostics confirms that all tests have been
named or identified in the test requisition form. performed or assayed with highest quality standards, clinical
2. All tests are performed and reported as per the safety & technical integrity.
turnaround time stated in the AGILUS Directory of Services. 6. Laboratory results should not be interpreted in isolation;
3. Result delays could occur due to unforeseen it must be correlated with clinical information and be
circumstances such as non-availability of kits / equipment interpreted by registered medical practitioners only to
breakdown / natural calamities / technical downtime or any determine final diagnosis.
other unforeseen event. 7. Test results may vary based on time of collection,
4. A requested test might not be performed if: physiological condition of the patient, current medication or
i. Specimen received is insufficient or inappropriate nutritional and dietary changes. Please consult your doctor
ii. Specimen quality is unsatisfactory or call us for any clarification.
iii. Incorrect specimen type 8. Test results cannot be used for Medico legal purposes.
iv. Discrepancy between identification on specimen 9. In case of queries please call customer care
container label and test requisition form (91115 91115) within 48 hours of the report.
.
Agilus Diagnostics Ltd
Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062
Page 6 Of 6
[Link] Pasari, MD
Consultant Pathologist
View Details View Report
PERFORMED AT :
Agilus Diagnostics Ltd
Gate No 2, Residency Area, Opp. St. Raphaels School,
Indore, 452001 ULR No.775000013358972-0290
Madhya Pradesh, India
Tel : 0731 2490008
